Some say the PBM industry is going through a dramatic evolution, and David Calabrese, RPh, MPH, vice president of clinical services for the non-profit pharmacy benefit management company MedMetrics Health Partners, is helping to keep the pace. Several strong influences are creating the evolution, and PBMs have responded with a new business model to meet the demands for greater transparency, shedding some light on the cost and value issues involved in pharmacy benefits.
Calabrese, a MANAGED HEALTHCARE EXECUTIVE Editorial Advisor, says there is an unacceptably high level of distrust and dissatisfaction among PBM customers. "Mounting lawsuits and fines waged against the for-profit PBM industry leaders, as well as a hostile regulatory environment, have exposed a number of previously unrecognized PBM business practices, which have fueled the fires of this distrust and created a strong call from managed care, employers and government leaders for a new and different PBM business model," he says.
A. The newly emerging PBM is one designed to overcome most, if not all, of the shortcomings and criticisms of the current PBM business model. It is one that strives to create a higher level of trust by aligning the PBM's financial incentives with its clientele. While many of the larger PBMs have developed 'pledges' to operate under a more transparent and ethically sound business strategy, the new breed of PBM will go beyond such cursory pledges by establishing a more truly transparent, fully pass-through, and accountable business model. Contracts between the new PBM model and its clients will be based largely upon per-member-per-month (PMPM) administrative fees and mutually developed performance standards. The new PBM will de-emphasize the focus on pharmacy spread, manufacturer rebates and per-claim administrative fees, and shift that focus toward driving the most cost-effective, evidence-based care possible in partnership with its clients.
Q. How would you define 'transparency'?
A. Transparency is a form of business practice involving full disclosure of costs and revenues, allowing the customer to make more well-informed decisions regarding purchases. In the PBM industry, transparency lays the groundwork for more simplified PBM-client business relations, more accurate financial modeling and performance metrics and a greater comfort level among PBM consumers. 'Transparency,' however, is a relative term used freely in the marketing efforts of many PBMs. The genuine commitment to transparency lies in the actual business practices the PBM invokes to support this claim. 'True transparency' is a model in which all PBM revenue streams [drug-level rebates, funding of clinical programs, administrative fees, service fees, management fees, research/educational grants, etc.] are fully disclosed to the payer; the full value of retail and mail-order pharmacy discounts is passed onto the client; data is shared with the client; and the client is given ultimate decision-making control over its drug benefit design and formulary management. It is this commitment to true transparency which has begun to differentiate newer PBMs.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
The Growing Popularity of Non-hormonal Menopause Therapy
February 12th 2025Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
February 12th 2025Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is priced at $3.2 million per dose, produced $821 million in net product revenue for the company in 2024.
Read More